Aptorum Group (APM) Competitors $0.93 +0.03 (+2.87%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock APM vs. LPCN, JATT, MTEX, NRSN, VYNE, CVM, PASG, SNYR, GELS, and LEXXShould you be buying Aptorum Group stock or one of its competitors? The main competitors of Aptorum Group include Lipocine (LPCN), JATT Acquisition (JATT), Mannatech (MTEX), NeuroSense Therapeutics (NRSN), VYNE Therapeutics (VYNE), CEL-SCI (CVM), Passage Bio (PASG), Synergy CHC Corp. (Uplisting) (SNYR), Gelteq (GELS), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Aptorum Group vs. Lipocine JATT Acquisition Mannatech NeuroSense Therapeutics VYNE Therapeutics CEL-SCI Passage Bio Synergy CHC Corp. (Uplisting) Gelteq Lexaria Bioscience Aptorum Group (NASDAQ:APM) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment. Which has preferable earnings and valuation, APM or LPCN? Aptorum Group has higher earnings, but lower revenue than Lipocine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptorum Group$430K11.59-$2.83MN/AN/ALipocine$3.67M5.27-$16.35M-$1.02-3.55 Does the MarketBeat Community believe in APM or LPCN? Lipocine received 306 more outperform votes than Aptorum Group when rated by MarketBeat users. However, 68.33% of users gave Aptorum Group an outperform vote while only 66.73% of users gave Lipocine an outperform vote. CompanyUnderperformOutperformAptorum GroupOutperform Votes4168.33% Underperform Votes1931.67% LipocineOutperform Votes34766.73% Underperform Votes17333.27% Which has more volatility and risk, APM or LPCN? Aptorum Group has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Do institutionals and insiders believe in APM or LPCN? 3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 64.0% of Aptorum Group shares are held by company insiders. Comparatively, 6.1% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer APM or LPCN? In the previous week, Lipocine had 1 more articles in the media than Aptorum Group. MarketBeat recorded 1 mentions for Lipocine and 0 mentions for Aptorum Group. Aptorum Group's average media sentiment score of 0.00 equaled Lipocine'saverage media sentiment score. Company Overall Sentiment Aptorum Group Neutral Lipocine Neutral Do analysts rate APM or LPCN? Lipocine has a consensus price target of $10.00, indicating a potential upside of 176.24%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than Aptorum Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is APM or LPCN more profitable? Aptorum Group's return on equity of 0.00% beat Lipocine's return on equity.Company Net Margins Return on Equity Return on Assets Aptorum GroupN/A N/A N/A Lipocine N/A -19.17%-17.60% SummaryLipocine beats Aptorum Group on 8 of the 14 factors compared between the two stocks. Get Aptorum Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APM vs. The Competition Export to ExcelMetricAptorum GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.98M$6.49B$5.36B$8.39BDividend YieldN/A2.66%5.22%4.10%P/E RatioN/A8.9426.5919.72Price / Sales11.59251.55391.61116.20Price / CashN/A65.8538.2534.62Price / Book0.316.466.794.51Net Income-$2.83M$143.98M$3.23B$248.18M7 Day Performance-10.38%3.16%4.03%1.14%1 Month Performance8.35%7.60%12.22%15.07%1 Year Performance-75.79%-2.36%16.76%6.59% Aptorum Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APMAptorum Group0.3473 of 5 stars$0.93+2.9%N/A-81.2%$4.98M$430,000.000.0030LPCNLipocine1.559 of 5 stars$3.63-9.0%$10.00+175.5%-42.9%$19.42M$3.67M-4.7810JATTJATT AcquisitionN/A$1.11-7.5%N/A-82.1%$19.15MN/A0.003High Trading VolumeMTEXMannatech0.6856 of 5 stars$9.93-5.9%N/A+18.3%$18.88M$117.87M-12.26250Analyst ForecastGap UpNRSNNeuroSense Therapeutics2.7672 of 5 stars$1.37+3.8%$14.00+921.9%+29.4%$18.72MN/A-2.1410VYNEVYNE Therapeutics1.9755 of 5 stars$1.22flat$6.25+412.3%-57.9%$18.56M$605,000.00-1.4230High Trading VolumeCVMCEL-SCIN/A$0.20-8.6%N/A-86.4%$18.55MN/A-0.4243News CoverageHigh Trading VolumePASGPassage Bio2.1118 of 5 stars$0.30-1.3%$7.50+2,416.8%-76.0%$18.52MN/A-0.25130SNYRSynergy CHC Corp. (Uplisting)N/A$2.11-11.3%$10.00+373.9%N/A$18.47M$34.83M0.0040Positive NewsEarnings ReportAnalyst RevisionGap DownGELSGelteqN/A$1.88-1.6%N/AN/A$17.74MN/A0.00N/AGap UpLEXXLexaria Bioscience2.0366 of 5 stars$1.00-1.0%$7.00+600.0%-66.4%$17.74M$525,923.00-2.007Gap Up Related Companies and Tools Related Companies LPCN Competitors JATT Competitors MTEX Competitors NRSN Competitors VYNE Competitors CVM Competitors PASG Competitors SNYR Competitors GELS Competitors LEXX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APM) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptorum Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APM Stock Free APM Stock Alerts